Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

NCT00732641 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

244

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Peginterferon

Sponsor

Merck Sharp & Dohme LLC